Early detection decreases breast cancer death. The ACR recommends annual screening
beginning at age 40 for women of average risk and earlier and/or more intensive screening …

OBJECTIVE. Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and
lobular carcinoma in situ (LCIS) are among high-risk lesions that have been previously …

Pathologists have the potential to play a critical role in refining appropriate therapy for
lesions in the atypical ducal hyperplasia-ductal carcinoma in situ (ADH-DCIS) spectrum by …

Objective: To review breast cancer incidence in women with ADH diagnosed by CNB and
managed nonoperatively. Background: ADH found on CNB is associated with an upgrade to …

Background Atypical ductal hyperplasia diagnosed on percutaneous breast biopsy typically
undergoes surgical excision, upgrading to invasive breast cancer or ductal carcinoma in situ …

BACKGROUND. Digital breast tomosynthesis (DBT) has led to increased detection and
biopsy of architectural distortion, which may yield malignancy, radial scar, or other benign …

Purpose To investigate clinical, radiologic and pathologic features of B3 lesions diagnosed
on VABB targeting microcalcifications, for identifying predictors of malignancy. Method This …

Background Oncologic safety of active monitoring (AM) for atypical ductal hyperplasia (ADH)
on core-needle biopsy (CNB) is not well defined. We sought to define oncologic outcomes …

Background The core-needle biopsy (CNB) diagnosis of atypical ductal hyperplasia (ADH)
generally mandates follow-up excision, but controversy exists on whether small foci of ADH …

The management of atypical breast lesions identified on core needle biopsy (CNB) for a
breast imaging abnormality is a topic of controversy. While all these atypical lesions have …